Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Wilfredo F. Garcia-Beltran et al.
Summary: Recent surveillance has identified the emergence of the SARS-CoV-2 Omicron variant, which carries up to 36 mutations in the spike protein and has the potential to evade vaccine-induced immunity. This study found that individuals vaccinated with mRNA vaccines exhibited strong neutralization of the Omicron variant, while most vaccinees had weak neutralization. The study also revealed that the Omicron variant infects more efficiently than other tested variants.
Article
Medicine, General & Internal
Emma K. Accorsi et al.
Summary: Assessing the performance of COVID-19 vaccines against the Omicron variant is crucial for public health guidance. This study found that receiving three doses of mRNA COVID-19 vaccine was associated with a lower likelihood of symptomatic SARS-CoV-2 infection compared to being unvaccinated or receiving two doses. These findings suggest that three doses of mRNA vaccine provide protection against both Omicron and Delta variants, though the protection against Omicron may be slightly lower.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Medicine, General & Internal
Nicole Wolter et al.
Summary: According to data analysis from South Africa, individuals infected with the omicron variant have a lower likelihood of hospitalization compared to those infected with non-omicron variants. Furthermore, individuals infected with the omicron variant have a lower odds of severe disease compared to individuals infected with the earlier delta variant.
Article
Multidisciplinary Sciences
Kenrie P. Y. Hui et al.
Summary: SARS-CoV-2 variants pose a threat to global public health. The Omicron variant replicates faster in bronchi but less efficiently in the lung parenchyma compared to other variants. All variants of concern have similar cellular tropism.
Letter
Medicine, General & Internal
Shirley Collie et al.
Summary: Preliminary data from a test-negative study design in South Africa showed that two doses of the BNT162b2 vaccine had an efficacy of 50 to 70% against hospitalization caused by the omicron variant in Gauteng province.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Public, Environmental & Occupational Health
Mark G. Thompson et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2022)
Article
Health Care Sciences & Services
Katia J. Bruxvoort et al.
Summary: Background Phase 3 trials have shown that mRNA-1273 is highly effective in preventing COVID-19. A cohort study conducted at Kaiser Permanente Southern California (KPSC) found that mRNA-1273 is also highly effective in preventing COVID-19 infection and severe disease in the real world. The study showed that the vaccine has a VE of 87.4% against COVID-19 infection, 95.8% against COVID-19 hospitalization, and 97.9% against COVID-19 hospital death.
LANCET REGIONAL HEALTH-AMERICAS
(2022)
Article
Medicine, General & Internal
Katia J. Bruxvoort et al.
Summary: The study evaluated the effectiveness of mRNA-1273 vaccine against SARS-CoV-2 variants, especially the delta variant, by time since vaccination. Two doses of the vaccine showed high effectiveness against all variants, with a decline in effectiveness against delta variant over time. One dose of the vaccine also demonstrated moderate effectiveness against delta infection.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Public, Environmental & Occupational Health
Joseph A. Lewnard et al.
Summary: Observational studies on COVID-19 vaccine effectiveness face challenges such as misclassification and confounding, which should be addressed through practical strategies at both study design and analysis stages to reduce bias. Traditional case-control and test-negative design studies may encounter important threats to validity, particularly in the context of SARS-CoV-2 infection and COVID-19 natural history parameters.
Article
Public, Environmental & Occupational Health
Geoffrey French et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Article
Medicine, General & Internal
H. M. El Sahly et al.
Summary: The mRNA-1273 vaccine demonstrated high efficacy in preventing COVID-19 illness and severe disease, with more than 5 months of protection and a good safety profile, including protection against asymptomatic infection.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Public, Environmental & Occupational Health
Sheena G. Sullivan et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY
(2016)
